NCT07443436: Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants
- State
- Not started
- Phase
- Phase 2
- People
- 30 planned
- Started
- 1 Nov 2026
- Primary completion
- 1 Nov 2027
- Arms
- Prednisone 10 mg/day -Hydroxychloroquine 400 mg/day - Azithromycin 250mg*3
- Results
- None posted
- 2 Mar 2026: Trial registered